Small-Fiber NeuropathyWIWT-SFNNCT07255573
Diagnostic Accuracy of The Water Immersion Wrinkle Test for Small Fiber Neuropathy
An observational study of Small-Fiber Neuropathy and Dysautonomia, run by HOSPITAL BRITANICO DE BUENOS AIRES at 1 site in Argentina.
Trial summary
Small-fiber neuropathy (SFN) affects A-delta and C fibers and commonly presents with sensory symptoms and dysautonomia. Confirmation often relies on specialized tests such as quantitative sensory testing (QST) and sympathetic skin response (SSR). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Small-Fiber Neuropathy, Dysautonomia
- How many people
- 38 participants
- Where
- 1 siteArgentina
- Study dates
- 1 Nov 2024to 20 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults evaluated at the Neuromuscular Department and Neurophysiology Laboratory of Hospital Británico de Buenos Aires (Argentina), a tertiary referral center. The source population includes consecutive clinic patients referred for assessment of suspected small-fiber neuropathy and healthy adult volunteers recruited from the hospital community. Recruitment occurs during routine outpatient activity; all index/comparator testing is performed on site.
Who may be able to join
- Age ≥ 18 years.
- Suspicion of small-fiber neuropathy based on history and/or physical examination by a neuromuscular neurology specialist.
- Sensory and motor nerve conduction studies within normal limits.
- Prior QST performed, regardless of result.
- Prior SSR performed, regardless of result.
Who cannot join
- Patients under 18 years.
- Individuals who do not wish to participate in the study or who decline informed consent.
- Patients with any contraindication to any of the aforementioned studies.
- Neurophysiological studies demonstrating large-fiber involvement.
Trial locations and contacts
1 site in 1 country.
Argentina1 site
Hospital Britanico de Buenos Aires
Buenos Aires, Buenos Aires F.D., 1428
About this study
Official title: Diagnostic Accuracy of The Water Immersion Wrinkle Test for the Diagnosis of Small Fiber Neuropathy
Small-fiber neuropathy (SFN) affects A-delta and C fibers and commonly presents with sensory symptoms and dysautonomia. Confirmation often relies on specialized tests such as quantitative sensory testing (QST) and sympathetic skin response (SSR). This prospective, single-center observational diagnostic-accuracy study will estimate the performance of the Water-Immersion Wrinkle Test (WIWT) for detecting SFN in adults evaluated by a neuromuscular service. The composite reference standard is specialist clinical assessment plus abnormality on ≥1 validated scale (Utah Early Neuropathy Scale [UENS] or modified Toronto Clinical Neuropathy Score [mTCNS]). The index procedure (WIWT) is standardized as follows: both hands immersed to at least the distal interphalangeal crease for 15 minutes; immersion begins at 43-44 °C with expected passive cooling of ~2 °C every 5 minutes; temperature measured at 0, 5, 10 and 15 minutes; no water is added or replaced during immersion. After gentle drying, standardized photographs are obtained and wrinkling grades (0-4) are recorded for digits 2-5; the bilateral summed score is classified abnormal <24 and normal ≥24. Examiners for WIWT, QST, and SSR are mutually blinded. The primary outcome is WIWT sensitivity and specificity versus the composite reference at baseline. Secondary outcomes include ROC area under the curve (AUC), positive/negative predictive values, and inter- and intra-rater reliability (intraclass correlation coefficients). Recruitment is ongoing; anticipated primary completion: November 2025.
Read the detailed description
This is a prospective, single-center, observational diagnostic-accuracy study designed to estimate the performance of the Water-Immersion Wrinkle Test (WIWT) for identifying small-fiber neuropathy (SFN) in adults evaluated by a neuromuscular department. The composite reference standard is a specialist clinical assessment consistent with SFN together with abnormality on at least one validated clinical scale (Utah Early Neuropathy Scale [UENS] or modified Toronto Clinical Neuropathy Score [mTCNS]). Quantitative Sensory Testing (QST) and Sympathetic Skin Response (SSR) are obtained as comparator tests but do not form part of the reference standard. The study adheres to STARD principles for diagnostic-accuracy research and uses predefined operating procedures for test execution, data capture, and analysis.
Study setting and workflow Participants are evaluated in the neuromuscular clinic of a tertiary hospital. The study uses a baseline-only design: all index and comparator tests are completed on the same day whenever feasible. A separate reliability session for image scoring occurs 48 hours to 7 days later without additional patient visits. The overall workflow is: (1) confirm eligibility and obtain consent; (2) complete standardized neurological examination and clinical scales; (3) perform or verify QST and SSR (irrespective of results); (4) perform WIWT; (5) acquire standardized fingertip photographs; (6) independent scoring of images by trained raters; (7) data entry and validation; (8) statistical analysis according to the prespecified plan.
Reference standard (composite) The reference standard integrates the treating neuromuscular specialist's judgment (history and examination) with at least one abnormal clinical scale among UENS or mTCNS using their published scoring rules. The scales are administered per their manuals by personnel trained on test instructions and scoring conventions. The reference standard classification (SFN vs no SFN) is recorded in a dedicated adjudication form. Test operators for WIWT, QST, and SSR do not have access to the reference classification at the time of testing.
Index test: WIWT-technical conduct Participants are seated upright. Both hands are immersed, at least to the distal interphalangeal crease, in water for 15 minutes. Before immersion, the skin is verified to be clean and completely dry. Hands are kept relaxed (neutral finger posture) and fingertips must not press against container surfaces. Because a thermostatically controlled bath is not available, immersion begins at 43-44 °C with expected passive cooling of approximately 2 °C every 5 minutes, targeting an end temperature of about 37-38 °C. Water temperature is measured with the service thermometer at 0, 5, 10 and 15 minutes to confirm the intended range. No water is added or replaced during immersion. A calibrated stopwatch is used to time the procedure. At completion, hands are gently patted dry and standardized photographs are obtained of the palmar distal phalanges of digits 2-5 of both hands. Environmental conditions are kept stable (indoor room, typical ambient temperature, indirect lighting) and recorded on the source form.
Image acquisition and standardization Photographs are taken with the clinic's digital camera or smartphone following a fixed template: (a) distance approximately 20-25 cm from fingertips; (b) camera aligned perpendicular to the palmar surface to minimize parallax; (c) neutral, diffuse illumination avoiding hard shadows; (d) inclusion of a 1-cm scale marker within the frame; (e) focus lock on the distal pad of each fingertip. Raw images are immediately reviewed for motion blur or framing errors and repeated if necessary before the participant leaves. Images are stored as high-resolution JPEG or HEIC (≥8 MP), transferred to the secure institutional drive, and automatically renamed by a deterministic convention (StudyID_Hand_Side_Digit_Timepoint.ext). No patient identifiers appear in filenames or image content.
Scoring rubric and rater training Wrinkling is graded on a 0-4 ordinal scale for digits 2-5 of each hand by trained raters who are not involved in the clinical reference assessment and are mutually blinded to QST/SSR results. Raters complete a short training using a curated set of example photographs with consensus labels, followed by a calibration exercise (≥20 images) with feedback until predefined agreement thresholds are met. For each participant, per-hand sums are computed and a bilateral summed score is derived; the bilateral classification threshold uses the prespecified rule (abnormal < 24; normal ≥ 24). For the reliability substudy, four raters independently score all images twice, separated by 48 hours to 7 days, with the second session presented in a randomized order to reduce recall. The image set used for the second session is identical to the first and contains no new photographs.
Comparator tests (QST and SSR) QST includes thermal detection thresholds and vibration thresholds measured with the clinic's standard equipment following manufacturer instructions and local laboratory SOPs, with device daily checks documented in the logbook. SSR is recorded from palmar electrodes with standard filter settings and sweep parameters; amplitude and latency are extracted according to laboratory conventions. Operators of QST and SSR are independent from the WIWT team and do not access the WIWT photographs or scores.
Bias mitigation and blinding To limit review and incorporation biases, the reference standard is defined a priori and does not include WIWT, QST, or SSR results. The WIWT examiner is masked to the reference classification and to QST/SSR readings; QST and SSR operators are masked to each other and to WIWT; image raters receive only coded image sets stripped of metadata. The order of WIWT versus QST/SSR is not fixed and is recorded to explore potential order effects. All analysis code and decision rules (for exclusions, tie handling, and outlier management) are prespecified.
Data collection and management Data are captured on paper case-report forms (CRFs) and transcribed into a REDCap-like electronic database hosted on the institutional server with user authentication, role-based access, and full audit trails. Double-data entry is applied to primary variables (reference classification, WIWT summed score, UENS/mTCNS totals); discrepancies are resolved by a third reviewer using the source documents. Automated data-validation rules check ranges (for example, temperature values at 0/5/10/15 minutes, test duration = 15 ± 1 min, score ranges 0-4 per digit), internal consistency (for example, bilateral sum equals the sum of component digits), and logical constraints (for example, no missing both "start temperature" and "end temperature"). A data dictionary defines variable names, formats, allowable codes, derivations, and edit checks. Versioning is handled at the database level; all changes after database lock require change-control approval and generate an audit entry.
Sample size rationale The planned sample size is approximately 30 participants, selected to provide acceptable precision for sensitivity and specificity estimates under plausible operating characteristics (for example, sensitivity ~0.80 and specificity ~0.70) with two-sided 95% confidence intervals of roughly ±0.10 under anticipated case-mix. The final sample size also accommodates the reliability substudy, ensuring that the number of images and raters provides adequate precision for intraclass correlation coefficients (ICCs) with confidence-interval widths ≤0.15 under expected variance components.
Statistical analysis overview Analyses are prespecified. For the primary diagnostic-accuracy analysis, WIWT is evaluated against the composite reference standard. Sensitivity, specificity, and their exact or 95% confidence intervals are reported at the prespecified bilateral sum threshold. ROC analysis treats the bilateral summed WIWT score as a continuous predictor; AUC and 95% CI are computed using non-parametric methods. Positive and negative predictive values are reported at the observed prevalence. Inter-rater reliability for the bilateral summed score uses a two-way random-effects, absolute-agreement ICC [ICC(2,1)], and intra-rater reliability uses a two-way mixed-effects ICC [ICC(3,1)] with 95% confidence intervals derived from ANOVA variance components; secondary reliability metrics (weighted kappa for ordinal per-digit grades) may be reported descriptively. Prespecified sensitivity analyses include: (a) exclusion of protocol-deviant WIWT runs (temperature/time deviations); (b) alternative temperature-window definitions; and (c) alternative classification cut-points explored descriptively without redefining the primary analysis. No hypothesis testing for between-test differences is required for the primary objective; if performed, comparisons of AUCs will use DeLong's method.
Data governance, confidentiality, and archiving All study data are de-identified at the point of storage; linkage files mapping StudyID to personal identifiers reside in a separate restricted directory accessible only to the clinical team. Photographs do not contain faces or unique marks beyond fingertip skin; rings and nail polish are removed when possible. Data are retained for the period required by institutional policy and local regulations. Access to the final analytic dataset and code is restricted to the analysis team; requests for de-identified data after publication follow the data-sharing statement entered elsewhere in the record.
Risk assessment and safety reporting WIWT, QST, and SSR are non-invasive procedures with minimal risk (primarily transient discomfort or skin maceration). Adverse events related to testing are expected to be rare and mild; any unexpected events temporally related to test execution are documented in the source forms and reported per institutional policy. The study does not use a formal data monitoring committee given its minimal-risk, non-interventional design.
Study timeline Recruitment is ongoing. Baseline testing and image acquisition occur on the day of enrollment; reliability scoring occurs within 48 hours to 7 days. Database lock is planned shortly after the anticipated primary completion date. The record will be updated as major milestones are reached (for example, changes in enrollment target, completion dates, or analysis plan).
- Conditions
- Small-Fiber Neuropathy, Dysautonomia
- Keywords
- small-fiber neuropathy, dysautonomia, water-immersion wrinkle test, QST, SSR
- Medical subject headings
- Small Fiber Neuropathy, Autonomic Nervous System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SFN Group | Adults evaluated in a tertiary neuromuscular clinic who, after baseline assessment, are classified as having small-fiber neuropathy (SFN) by the prespecified composite reference standard. The reference integrates (1) neuromuscular specialist clinical judgment (history and focused examination) and (2) abnormality on ≥1 validated scale (UENS or mTCNS) using published scoring rules. Group assignment is independent of WIWT, QST, or SSR results; these tests may be performed as index/comparator procedures but do not define cohort membership. | |
| Control Group | Adults evaluated in a tertiary neuromuscular clinic who, after baseline assessment, are classified as No Small-Fiber Neuropathy (No SFN) by the prespecified composite reference. This cohort includes healthy adult volunteers with no neuropathic symptoms or signs, a normal neurological examination, and normal UENS and mTCNS scores per published rules. Group assignment is independent of WIWT, QST, or SSR results; these tests may be performed as index/comparator procedures but do not define cohort membership. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity and specificity of WIWT (%) vs composite reference (clinical + UENS/mTCNS abnormality)
WIWT scoring: Each fingertip (digits 2-5 of both hands) is graded 0-4 after immersion (0 = no wrinkling; 4 = marked wrinkling). Per-hand sum 0-16; bilateral sum 0-32 (higher = more wrinkling/normal sympathetic function). Threshold to define test result: bilateral sum <24 = abnormal, ≥24 = normal.
Procedure: Hands immersed 15 min, starting 43-44 °C with passive cooling ≈2 °C/5 min to ~37-38 °C; temperature checked at 0, 5, 10 min; no water added or replaced; standardized photographs scored by blinded raters.
Reference standard: Neuromuscular specialist clinical assessment plus abnormality on ≥1 validated scale (UENS or mTCNS).
Metrics: Sensitivity = TP/(TP+FN); Specificity = TN/(TN+FP); both reported as percent (%) with 95% CIs.
Measured: Baseline (single visit; same-day completion of all tests)
Secondary outcomes (5)
ROC Area Under the Curve (AUC) for WIWT
ROC curve of WIWT (continuous summed score) vs. reference standard; AUC with 95% CI using non-parametric methods.
Measured: Baseline
Positive and Negative Predictive Values (PPV, NPV) of WIWT
PPV = TP/(TP+FP); NPV = TN/(TN+FN) with 95% CIs at observed SFN prevalence in the study sample.
Measured: Baseline
Inter-rater Reliability of WIWT Wrinkle Scoring (ICC)
Four trained raters score standardized fingertip photographs; ICC(2,1), absolute agreement for summed wrinkle scores (digits 2-5 per hand; bilateral sum).
Measured: Within 7 days (two image-rating sessions separated by 48 h-7 days).
Intra-rater Reliability of WIWT Wrinkle Scoring (ICC)
Same rater re-scores identical image set; ICC(3,1)
Measured: 48 h-7 days between sessions.
Comparative Diagnostic Performance: WIWT vs QST and SSR (AUC, Se/Sp)
At baseline, for each test (WIWT, QST, SSR) ROC curves are constructed against the composite reference (specialist assessment + abnormal UENS or mTCNS). AUCs with 95% CIs are reported and pairwise AUC comparisons (WIWT vs QST; WIWT vs SSR; QST vs SSR). Using prespecified thresholds-WIWT bilateral sum <24 = abnormal; QST abnormal per laboratory normative cut-offs; SSR abnormal if absent -we compute sensitivity and specificity (%, 95% CIs).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2025
- Study start1 Nov 2024
- Primary completion1 Nov 2025
- Study completion20 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (17)Papers the sponsor has linked to this study.
- Other trials for Small-Fiber NeuropathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 38 participants (actual)
Sponsor and investigators
- Lead sponsor
- HOSPITAL BRITANICO DE BUENOS AIRES
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lucas Piedrafita Vico, HOSPITAL BRITANICO DE BUENOS AIRES
- Investigators
- Lucas A Piedrafita Vico, MD, Principal investigator, Hospital Británico de Buenos Aires
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07255573
- Sponsor's protocol ID
- 14202
- Acronym
- WIWT-SFN
- Status last verified
- Dec 2025
- First submitted
- 20 Nov 2025
- Last updated
- 8 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: De-identified individual data underlying the primary results may be shared upon reasonable request after publication for 36 months; data dictionary and analytic code available on request.
Publications
Piedrafita Vico LA, Reisin R, Gonorazky S. Teaching NeuroImage: Absence of Wrinkles in Small Fiber Neuropathy. Neurology. 2022 Nov 22;99(21):962-963. doi: 10.1212/WNL.0000000000201320. Epub 2022 Sep 13. No abstract available.
PubMed 36100436Clark CV, Pentland B, Ewing DJ, Clarke BF. Decreased skin wrinkling in diabetes mellitus. Diabetes Care. 1984 May-Jun;7(3):224-7. doi: 10.2337/diacare.7.3.224.
PubMed 6734390Braham J, Sadeh M, Sarova-Pinhas I. Skin wrinkling on immersion of hands: a test of sympathetic function. Arch Neurol. 1979 Feb;36(2):113-4. doi: 10.1001/archneur.1979.00500380083013.
PubMed 420620Teoh HL, Chow A, Wilder-Smith EP. Skin wrinkling for diagnosing small fibre neuropathy: comparison with epidermal nerve density and sympathetic skin response. J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):835-7. doi: 10.1136/jnnp.2007.140947. Epub 2008 Feb 12.
PubMed 18270233Wilder-Smith EP, Guo Y, Chow A. Stimulated skin wrinkling for predicting intraepidermal nerve fibre density. Clin Neurophysiol. 2009 May;120(5):953-8. doi: 10.1016/j.clinph.2009.03.011. Epub 2009 Apr 16.
PubMed 19375384Wilder-Smith EP. Stimulated skin wrinkling as an indicator of limb sympathetic function. Clin Neurophysiol. 2015 Jan;126(1):10-6. doi: 10.1016/j.clinph.2014.08.007. Epub 2014 Sep 2.
PubMed 25216595Cales L, Weber RA. Effect of water temperature on skin wrinkling. J Hand Surg Am. 1997 Jul;22(4):747-9. doi: 10.1016/s0363-5023(97)80141-4.
PubMed 9260639Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, Howard J, Smith AG. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008 Sep;13(3):218-27. doi: 10.1111/j.1529-8027.2008.00180.x.
PubMed 18844788Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V. Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. Eur J Neurol. 2018 Mar;25(3):484-490. doi: 10.1111/ene.13533. Epub 2017 Dec 26.
PubMed 29194856Galosi E, Falco P, Di Pietro G, Leone C, Esposito N, De Stefano G, Di Stefano G, Truini A. The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN-SIQ) for identifying pure small fiber neuropathy. J Peripher Nerv Syst. 2022 Dec;27(4):283-290. doi: 10.1111/jns.12513. Epub 2022 Oct 5.
PubMed 36175394Bril V, Tomioka S, Buchanan RA, Perkins BA; mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009 Mar;26(3):240-6. doi: 10.1111/j.1464-5491.2009.02667.x.
PubMed 19317818Zilliox LA, Ruby SK, Singh S, Zhan M, Russell JW. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complications. 2015 Apr;29(3):372-7. doi: 10.1016/j.jdiacomp.2015.01.011. Epub 2015 Feb 3.
PubMed 25690405Novak P. Electrochemical skin conductance: a systematic review. Clin Auton Res. 2019 Feb;29(1):17-29. doi: 10.1007/s10286-017-0467-x. Epub 2017 Sep 26.
PubMed 28951985Terkelsen AJ, Karlsson P, Lauria G, Freeman R, Finnerup NB, Jensen TS. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol. 2017 Nov;16(11):934-944. doi: 10.1016/S1474-4422(17)30329-0.
PubMed 29029847Devigili G, Rinaldo S, Lombardi R, Cazzato D, Marchi M, Salvi E, Eleopra R, Lauria G. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain. 2019 Dec 1;142(12):3728-3736. doi: 10.1093/brain/awz333.
PubMed 31665231
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnostic Accuracy of The Water Immersion Wrinkle Test for the Diagnosis of Small Fiber Neuropathy
- ClinicalTrials.gov ID
- NCT07255573
- Acronym / sponsor ID
- WIWT-SFN / 14202
- Conditions
- Small-Fiber Neuropathy, Dysautonomia
- Keywords
- small-fiber neuropathy, dysautonomia, water-immersion wrinkle test, QST, SSR
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 38 participants (actual)
- Lead sponsor
- HOSPITAL BRITANICO DE BUENOS AIRESUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 20 Nov 2025 (actual)
- First posted
- 1 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Small-fiber neuropathy (SFN) affects A-delta and C fibers and commonly presents with sensory symptoms and dysautonomia. Confirmation often relies on specialized tests such as quantitative sensory testing (QST) and sympathetic skin response (SSR). This prospective, single-center observational diagnostic-accuracy study will estimate the performance of the Water-Immersion Wrinkle Test (WIWT) for detecting SFN in adults evaluated by a neuromuscular service. The composite reference standard is specialist clinical assessment plus abnormality on ≥1 validated scale (Utah Early Neuropathy Scale [UENS] or modified Toronto Clinical Neuropathy Score [mTCNS]). The index procedure (WIWT) is standardized as follows: both hands immersed to at least the distal interphalangeal crease for 15 minutes; immersion begins at 43-44 °C with expected passive cooling of ~2 °C every 5 minutes; temperature measured at 0, 5, 10 and 15 minutes; no water is added or replaced during immersion. After gentle drying, standardized photographs are obtained and wrinkling grades (0-4) are recorded for digits 2-5; the bilateral summed score is classified abnormal <24 and normal ≥24. Examiners for WIWT, QST, and SSR are mutually blinded. The primary outcome is WIWT sensitivity and specificity versus the composite reference at baseline. Secondary outcomes include ROC area under the curve (AUC), positive/negative predictive values, and inter- and intra-rater reliability (intraclass correlation coefficients). Recruitment is ongoing; anticipated primary completion: November 2025.
Detailed description
This is a prospective, single-center, observational diagnostic-accuracy study designed to estimate the performance of the Water-Immersion Wrinkle Test (WIWT) for identifying small-fiber neuropathy (SFN) in adults evaluated by a neuromuscular department. The composite reference standard is a specialist clinical assessment consistent with SFN together with abnormality on at least one validated clinical scale (Utah Early Neuropathy Scale [UENS] or modified Toronto Clinical Neuropathy Score [mTCNS]). Quantitative Sensory Testing (QST) and Sympathetic Skin Response (SSR) are obtained as comparator tests but do not form part of the reference standard. The study adheres to STARD principles for diagnostic-accuracy research and uses predefined operating procedures for test execution, data capture, and analysis.
Study setting and workflow Participants are evaluated in the neuromuscular clinic of a tertiary hospital. The study uses a baseline-only design: all index and comparator tests are completed on the same day whenever feasible. A separate reliability session for image scoring occurs 48 hours to 7 days later without additional patient visits. The overall workflow is: (1) confirm eligibility and obtain consent; (2) complete standardized neurological examination and clinical scales; (3) perform or verify QST and SSR (irrespective of results); (4) perform WIWT; (5) acquire standardized fingertip photographs; (6) independent scoring of images by trained raters; (7) data entry and validation; (8) statistical analysis according to the prespecified plan.
Reference standard (composite) The reference standard integrates the treating neuromuscular specialist's judgment (history and examination) with at least one abnormal clinical scale among UENS or mTCNS using their published scoring rules. The scales are administered per their manuals by personnel trained on test instructions and scoring conventions. The reference standard classification (SFN vs no SFN) is recorded in a dedicated adjudication form. Test operators for WIWT, QST, and SSR do not have access to the reference classification at the time of testing.
Index test: WIWT-technical conduct Participants are seated upright. Both hands are immersed, at least to the distal interphalangeal crease, in water for 15 minutes. Before immersion, the skin is verified to be clean and completely dry. Hands are kept relaxed (neutral finger posture) and fingertips must not press against container surfaces. Because a thermostatically controlled bath is not available, immersion begins at 43-44 °C with expected passive cooling of approximately 2 °C every 5 minutes, targeting an end temperature of about 37-38 °C. Water temperature is measured with the service thermometer at 0, 5, 10 and 15 minutes to confirm the intended range. No water is added or replaced during immersion. A calibrated stopwatch is used to time the procedure. At completion, hands are gently patted dry and standardized photographs are obtained of the palmar distal phalanges of digits 2-5 of both hands. Environmental conditions are kept stable (indoor room, typical ambient temperature, indirect lighting) and recorded on the source form.
Image acquisition and standardization Photographs are taken with the clinic's digital camera or smartphone following a fixed template: (a) distance approximately 20-25 cm from fingertips; (b) camera aligned perpendicular to the palmar surface to minimize parallax; (c) neutral, diffuse illumination avoiding hard shadows; (d) inclusion of a 1-cm scale marker within the frame; (e) focus lock on the distal pad of each fingertip. Raw images are immediately reviewed for motion blur or framing errors and repeated if necessary before the participant leaves. Images are stored as high-resolution JPEG or HEIC (≥8 MP), transferred to the secure institutional drive, and automatically renamed by a deterministic convention (StudyID_Hand_Side_Digit_Timepoint.ext). No patient identifiers appear in filenames or image content.
Scoring rubric and rater training Wrinkling is graded on a 0-4 ordinal scale for digits 2-5 of each hand by trained raters who are not involved in the clinical reference assessment and are mutually blinded to QST/SSR results. Raters complete a short training using a curated set of example photographs with consensus labels, followed by a calibration exercise (≥20 images) with feedback until predefined agreement thresholds are met. For each participant, per-hand sums are computed and a bilateral summed score is derived; the bilateral classification threshold uses the prespecified rule (abnormal < 24; normal ≥ 24). For the reliability substudy, four raters independently score all images twice, separated by 48 hours to 7 days, with the second session presented in a randomized order to reduce recall. The image set used for the second session is identical to the first and contains no new photographs.
Comparator tests (QST and SSR) QST includes thermal detection thresholds and vibration thresholds measured with the clinic's standard equipment following manufacturer instructions and local laboratory SOPs, with device daily checks documented in the logbook. SSR is recorded from palmar electrodes with standard filter settings and sweep parameters; amplitude and latency are extracted according to laboratory conventions. Operators of QST and SSR are independent from the WIWT team and do not access the WIWT photographs or scores.
Bias mitigation and blinding To limit review and incorporation biases, the reference standard is defined a priori and does not include WIWT, QST, or SSR results. The WIWT examiner is masked to the reference classification and to QST/SSR readings; QST and SSR operators are masked to each other and to WIWT; image raters receive only coded image sets stripped of metadata. The order of WIWT versus QST/SSR is not fixed and is recorded to explore potential order effects. All analysis code and decision rules (for exclusions, tie handling, and outlier management) are prespecified.
Data collection and management Data are captured on paper case-report forms (CRFs) and transcribed into a REDCap-like electronic database hosted on the institutional server with user authentication, role-based access, and full audit trails. Double-data entry is applied to primary variables (reference classification, WIWT summed score, UENS/mTCNS totals); discrepancies are resolved by a third reviewer using the source documents. Automated data-validation rules check ranges (for example, temperature values at 0/5/10/15 minutes, test duration = 15 ± 1 min, score ranges 0-4 per digit), internal consistency (for example, bilateral sum equals the sum of component digits), and logical constraints (for example, no missing both "start temperature" and "end temperature"). A data dictionary defines variable names, formats, allowable codes, derivations, and edit checks. Versioning is handled at the database level; all changes after database lock require change-control approval and generate an audit entry.
Sample size rationale The planned sample size is approximately 30 participants, selected to provide acceptable precision for sensitivity and specificity estimates under plausible operating characteristics (for example, sensitivity ~0.80 and specificity ~0.70) with two-sided 95% confidence intervals of roughly ±0.10 under anticipated case-mix. The final sample size also accommodates the reliability substudy, ensuring that the number of images and raters provides adequate precision for intraclass correlation coefficients (ICCs) with confidence-interval widths ≤0.15 under expected variance components.
Statistical analysis overview Analyses are prespecified. For the primary diagnostic-accuracy analysis, WIWT is evaluated against the composite reference standard. Sensitivity, specificity, and their exact or 95% confidence intervals are reported at the prespecified bilateral sum threshold. ROC analysis treats the bilateral summed WIWT score as a continuous predictor; AUC and 95% CI are computed using non-parametric methods. Positive and negative predictive values are reported at the observed prevalence. Inter-rater reliability for the bilateral summed score uses a two-way random-effects, absolute-agreement ICC [ICC(2,1)], and intra-rater reliability uses a two-way mixed-effects ICC [ICC(3,1)] with 95% confidence intervals derived from ANOVA variance components; secondary reliability metrics (weighted kappa for ordinal per-digit grades) may be reported descriptively. Prespecified sensitivity analyses include: (a) exclusion of protocol-deviant WIWT runs (temperature/time deviations); (b) alternative temperature-window definitions; and (c) alternative classification cut-points explored descriptively without redefining the primary analysis. No hypothesis testing for between-test differences is required for the primary objective; if performed, comparisons of AUCs will use DeLong's method.
Data governance, confidentiality, and archiving All study data are de-identified at the point of storage; linkage files mapping StudyID to personal identifiers reside in a separate restricted directory accessible only to the clinical team. Photographs do not contain faces or unique marks beyond fingertip skin; rings and nail polish are removed when possible. Data are retained for the period required by institutional policy and local regulations. Access to the final analytic dataset and code is restricted to the analysis team; requests for de-identified data after publication follow the data-sharing statement entered elsewhere in the record.
Risk assessment and safety reporting WIWT, QST, and SSR are non-invasive procedures with minimal risk (primarily transient discomfort or skin maceration). Adverse events related to testing are expected to be rare and mild; any unexpected events temporally related to test execution are documented in the source forms and reported per institutional policy. The study does not use a formal data monitoring committee given its minimal-risk, non-interventional design.
Study timeline Recruitment is ongoing. Baseline testing and image acquisition occur on the day of enrollment; reliability scoring occurs within 48 hours to 7 days. Database lock is planned shortly after the anticipated primary completion date. The record will be updated as major milestones are reached (for example, changes in enrollment target, completion dates, or analysis plan).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SFN Group | – | –Adults evaluated in a tertiary neuromuscular clinic who, after baseline assessment, are classified as having small-fiber neuropathy (SFN) by the prespecified composite reference standard. The reference integrates (1) neuromuscular specialist clinical judgment (history and focused examination) and (2) abnormality on ≥1 validated scale (UENS or mTCNS) using published scoring rules. Group assignment is independent of WIWT, QST, or SSR results; these tests may be performed as index/comparator procedures but do not define cohort membership. |
| Control Group | – | –Adults evaluated in a tertiary neuromuscular clinic who, after baseline assessment, are classified as No Small-Fiber Neuropathy (No SFN) by the prespecified composite reference. This cohort includes healthy adult volunteers with no neuropathic symptoms or signs, a normal neurological examination, and normal UENS and mTCNS scores per published rules. Group assignment is independent of WIWT, QST, or SSR results; these tests may be performed as index/comparator procedures but do not define cohort membership. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults evaluated at the Neuromuscular Department and Neurophysiology Laboratory of Hospital Británico de Buenos Aires (Argentina), a tertiary referral center. The source population includes consecutive clinic patients referred for assessment of suspected small-fiber neuropathy and healthy adult volunteers recruited from the hospital community. Recruitment occurs during routine outpatient activity; all index/comparator testing is performed on site.
Key inclusion criteria (5 listed)
- Age ≥ 18 years.
- Suspicion of small-fiber neuropathy based on history and/or physical examination by a neuromuscular neurology specialist.
- Sensory and motor nerve conduction studies within normal limits.
- Prior QST performed, regardless of result.
- Prior SSR performed, regardless of result.
Key exclusion criteria (4 listed)
- Patients under 18 years.
- Individuals who do not wish to participate in the study or who decline informed consent.
- Patients with any contraindication to any of the aforementioned studies.
- Neurophysiological studies demonstrating large-fiber involvement.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sensitivity and specificity of WIWT (%) vs composite reference (clinical + UENS/mTCNS abnormality)
Time frame: Baseline (single visit; same-day completion of all tests)
WIWT scoring: Each fingertip (digits 2-5 of both hands) is graded 0-4 after immersion (0 = no wrinkling; 4 = marked wrinkling). Per-hand sum 0-16; bilateral sum 0-32 (higher = more wrinkling/normal sympathetic function). Threshold to define test result: bilateral sum <24 = abnormal, ≥24 = normal. Procedure: Hands immersed 15 min, starting 43-44 °C with passive cooling ≈2 °C/5 min to ~37-38 °C; temperature checked at 0, 5, 10 min; no water added or replaced; standardized photographs scored by blinded raters. Reference standard: Neuromuscular specialist clinical assessment plus abnormality on ≥1 validated scale (UENS or mTCNS). Metrics: Sensitivity = TP/(TP+FN); Specificity = TN/(TN+FP); both reported as percent (%) with 95% CIs.
5 secondary outcomes
ROC Area Under the Curve (AUC) for WIWT
Time frame: Baseline
Positive and Negative Predictive Values (PPV, NPV) of WIWT
Time frame: Baseline
Inter-rater Reliability of WIWT Wrinkle Scoring (ICC)
Time frame: Within 7 days (two image-rating sessions separated by 48 h-7 days).
Intra-rater Reliability of WIWT Wrinkle Scoring (ICC)
Time frame: 48 h-7 days between sessions.
Comparative Diagnostic Performance: WIWT vs QST and SSR (AUC, Se/Sp)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2025.
- Background: PubMed 36100436Piedrafita Vico LA, Reisin R, Gonorazky S. Teaching NeuroImage: Absence of Wrinkles in Small Fiber Neuropathy. Neurology. 2022 Nov 22;99(21):962-963. doi: 10.1212/WNL.0000000000201320. Epub 2022 Sep 13. No abstract available.
- Background: PubMed 6734390Clark CV, Pentland B, Ewing DJ, Clarke BF. Decreased skin wrinkling in diabetes mellitus. Diabetes Care. 1984 May-Jun;7(3):224-7. doi: 10.2337/diacare.7.3.224.
- Background: PubMed 420620Braham J, Sadeh M, Sarova-Pinhas I. Skin wrinkling on immersion of hands: a test of sympathetic function. Arch Neurol. 1979 Feb;36(2):113-4. doi: 10.1001/archneur.1979.00500380083013.
- Background: PubMed 18270233Teoh HL, Chow A, Wilder-Smith EP. Skin wrinkling for diagnosing small fibre neuropathy: comparison with epidermal nerve density and sympathetic skin response. J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):835-7. doi: 10.1136/jnnp.2007.140947. Epub 2008 Feb 12.
- Background: PubMed 19375384Wilder-Smith EP, Guo Y, Chow A. Stimulated skin wrinkling for predicting intraepidermal nerve fibre density. Clin Neurophysiol. 2009 May;120(5):953-8. doi: 10.1016/j.clinph.2009.03.011. Epub 2009 Apr 16.
- Background: PubMed 25216595Wilder-Smith EP. Stimulated skin wrinkling as an indicator of limb sympathetic function. Clin Neurophysiol. 2015 Jan;126(1):10-6. doi: 10.1016/j.clinph.2014.08.007. Epub 2014 Sep 2.
- Background: PubMed 9260639Cales L, Weber RA. Effect of water temperature on skin wrinkling. J Hand Surg Am. 1997 Jul;22(4):747-9. doi: 10.1016/s0363-5023(97)80141-4.
- Background: PubMed 18844788Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, Howard J, Smith AG. The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. J Peripher Nerv Syst. 2008 Sep;13(3):218-27. doi: 10.1111/j.1529-8027.2008.00180.x.
- Background: PubMed 29194856Abraham A, Barnett C, Katzberg HD, Lovblom LE, Perkins BA, Bril V. Toronto Clinical Neuropathy Score is valid for a wide spectrum of polyneuropathies. Eur J Neurol. 2018 Mar;25(3):484-490. doi: 10.1111/ene.13533. Epub 2017 Dec 26.
- Background: PubMed 36175394Galosi E, Falco P, Di Pietro G, Leone C, Esposito N, De Stefano G, Di Stefano G, Truini A. The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN-SIQ) for identifying pure small fiber neuropathy. J Peripher Nerv Syst. 2022 Dec;27(4):283-290. doi: 10.1111/jns.12513. Epub 2022 Oct 5.
- Background: PubMed 19317818Bril V, Tomioka S, Buchanan RA, Perkins BA; mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009 Mar;26(3):240-6. doi: 10.1111/j.1464-5491.2009.02667.x.
- Background: PubMed 25690405Zilliox LA, Ruby SK, Singh S, Zhan M, Russell JW. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complications. 2015 Apr;29(3):372-7. doi: 10.1016/j.jdiacomp.2015.01.011. Epub 2015 Feb 3.
- Individual participant dataSharing planned: Undecided. De-identified individual data underlying the primary results may be shared upon reasonable request after publication for 36 months; data dictionary and analytic code available on request.
Related trials for Small-Fiber Neuropathy
Recruiting
Evaluation of the Prevalence, and Immunological Characteristics of Small Fiber Neuropathy in Patients With Primary Sjögren's Syndrome
Sjögren's Syndrome, Small Fiber Neuropathy
Recruiting
Magnetic Brain Stimulation in Small Fiber Neuropathy
Small Fiber Neuropathy
Recruiting
Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Not yet recruitingPhase 4
Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy
Neuropathy, Small Fiber, Diabete Mellitus
Enrolling by invitation
Pilot Study to Evaluate Changes in Intra-Epidermal Nerve Fiber Density (IENFD) in Patients With Small-Fiber Neuropathy
Small Fiber Neuropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lucas A Piedrafita Vico, MD principal investigator
Hospital Británico de Buenos Aires
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Small-Fiber Neuropathy and Dysautonomia, run by HOSPITAL BRITANICO DE BUENOS AIRES at 1 site in Argentina.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Argentina. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity and specificity of WIWT (%) vs composite reference (clinical + UENS/mTCNS abnormality) (time frame: Baseline (single visit; same-day completion of all tests)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07255573, which also lists 17 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2025.